Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Cencora ( (COR) ) is now available.
On January 20, 2026, Cencora’s board of directors appointed Ellen G. Cooper, Chairman, President and CEO of Lincoln Financial, as a new independent director, expanding the board from ten to eleven members; the company announced the move publicly on January 22, 2026. Cooper, a seasoned insurance executive with extensive risk management and financial expertise from senior roles at Lincoln Financial, Goldman Sachs Asset Management, AEGON Americas and Ernst & Young, will receive standard pro-rated compensation for non-employee directors and currently has no board committee assignments, while Cencora’s leadership highlights her appointment as a strategic reinforcement of the board’s depth as the company seeks to sustain long-term growth and strengthen its positioning as a leading healthcare company.
The most recent analyst rating on (COR) stock is a Buy with a $440.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Outperform.
The score is driven mainly by solid financial performance—especially strong cash flow generation—alongside supportive technical uptrend signals. This is moderated by a high valuation (elevated P/E and low yield) and balance-sheet leverage, while the latest earnings call was broadly positive due to raised guidance despite noted impairments and higher interest costs.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora is a leading global pharmaceutical solutions organization that partners with drug innovators across the value chain to facilitate and optimize market access to therapies. It provides secure, reliable delivery of pharmaceuticals, healthcare products and related solutions to care providers, serving both human and animal health markets. The company employs more than 51,000 people worldwide and is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, with annual revenue exceeding $300 billion.
Average Trading Volume: 1,417,302
Technical Sentiment Signal: Buy
Current Market Cap: $68.03B
Find detailed analytics on COR stock on TipRanks’ Stock Analysis page.